Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback